Siemens leads the way in molecular medicine, says Reinhardt
29 November 2005
Chicago, USA. "Siemens is leading the way in developing and
bringing to market healthcare innovations that will increase the quality of
life," said Dr. Erich Reinhardt, President and CEO of Siemens Medical
Solutions, at RSNA2005. "The future of healthcare relies on our ability to
utilize technology to understand disease earlier, develop the best treatment
plans, improve clinical workflow and decrease costs — and ultimately help
patients enjoy longer and healthier lives."
Siemens has assumed a leadership role in the evolution of molecular
medicine through the allocation of significant resources for research and
development and its strategic partnerships. The recent acquisition of
longtime partner CTI Molecular Imaging, Inc. marked a milestone in Siemens'
quest to forge new paths in molecular medicine.
"Along with our customers, we see the future of healthcare in molecular
medicine," said Reinhardt. "Our efforts in preclinical, clinical and
biomarker solutions will help to drive the discovery of new methods for
diagnosis and treatment of disease."
Molecular medicine is expected to assist physicians and researchers in the
understanding of the root causes of disease, rather than simply managing the
resulting conditions. Siemens is taking the lead in developing a
comprehensive set of diagnostic tools that include molecular imaging
techniques that will enable pre-symptomatic and early disease detection.
"We expect molecular imaging will lead not only to improved clinical
outcomes, but also could initiate a dramatic shift in the delivery of
healthcare from 'managing sickness' to a focus on maintaining wellness,"
said Michael Reitermann, president, Molecular Imaging Division, Siemens